Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

six TAAs-specific autologous T cells MT-601

A preparation of autologous, ex vivo-expanded, CD4- and CD8-positive T lymphocytes specific for six tumor-associated antigens (TAAs), with potential immunomodulating and antineoplastic activities. Upon administration of six TAAs-specific autologous T cells MT-601, the T cells target, bind to and induce selective toxicity in cancer cells overexpressing one or more of these six TAAs. By targeting more than one antigen, MT-601 may be able to induce a better and more durable anti-tumor response due to its ability to overcome antigen loss.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous T-cells-targeting six TAAs MT-601
multi-antigen specific CD4+ andCD8+ autologous T cells MT-601
multi-TAA-specific autologous T cells MT-601
multi-tumor-associated antigen-specific autologous T cells MT-601
Code name:MT 601
MT-601
MT601
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search